Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
about
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphomaThe aggressive peripheral T-cell lymphomas: 2013New antibody approaches to lymphoma therapyNew molecular insights into peripheral T cell lymphomasMonoclonal antibodies and progressive multifocal leukoencephalopathyThe changing landscape of progressive multifocal leukoencephalopathy.A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas.A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyRate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.Peripheral T-cell lymphoma: review and updates of current management strategiesPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesMonoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases.The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell NeoplasmsPrimary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.An update on the management of peripheral T-cell lymphoma and emerging treatment optionsHow I treat the peripheral T-cell lymphomasBortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapyTargeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELAA case of enteropathy-type T-cell lymphoma diagnosed by small bowel enteroscopy: a perspective on imaging-enhanced endoscopyClinical Trials and Treatment of ATL.Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond.Type I enteropathy-associated T-cell lymphoma in the colon of a 29-year-old patient and a brief literature review.Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.Receptor-directed therapy of T-cell leukemias and lymphomas.CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.New targets of therapy in T-cell lymphomas.
P2860
Q24633714-DF22611E-9812-47D4-B8A2-6D6B97165FFCQ27003257-0F1F8B55-3D57-4105-B2B8-F97B2DA72D99Q27022373-14973520-4CCD-4244-A631-02C601AAC052Q27026081-B992874D-02D5-4D74-A30B-66221D35FDE9Q28270413-F6316724-6977-4813-96E9-2DD38A3827DEQ30403035-8D4990BC-FBB1-4031-98AF-677991B04A87Q33388189-DFC3960F-0352-462B-BCA7-D7E4A930770BQ33396356-611E06CB-4809-450D-8CFA-D0BE596494FEQ33409982-CA46C666-AFE7-48ED-A974-403B7BFED31FQ33428066-F69FA03A-33E5-46C5-8360-423840151520Q33980435-EC194CBC-6234-41BF-9DB0-05CE814E9B29Q34222228-E1B9667F-8288-4F92-BB23-57954ABA764DQ34226010-FE413BA7-8D72-4C0A-BBD3-A402FA4A96B8Q34257135-1EED57BB-96C9-423F-94B4-09DB94575FD8Q34479082-DC7DF321-4494-4A16-AE72-0E86029CE067Q34532546-CE8C48DE-8651-44CF-8A44-81B332D68567Q34683488-C186DC9A-0E32-4A32-94FE-B6C4095B097AQ34700655-4C468EC1-2366-4552-B6BE-6C6C84834561Q35126129-D890A8E6-0C48-4977-83DE-C40793FF8A4EQ35163220-07B2EBB1-709C-4064-AEB8-FA143600B5B6Q35224833-146B2B7B-EA36-4F59-8E03-A6936F932547Q35683871-4B1999A9-7F20-41F9-9F93-24D3F914D539Q35865090-BA515E95-8517-46D4-8813-CD5471920951Q36110447-B20E1588-4CE6-417A-A5DE-1B1DB92DACAAQ36355093-26A00A93-D9D9-492F-B376-836929FE31B3Q36360736-3B2EE009-4B42-40FF-A85C-05B08ED586BAQ36365590-4BF8DAA6-3E33-4D69-9424-41F12919E821Q36366982-48D27907-5EAE-41BA-8036-34277C3C24E3Q36385208-EDC52F92-A494-4C4E-817E-31168D7084DFQ36422133-E9ACB993-768B-4281-AAB0-650F0BB533C5Q36612584-EF36CA3C-A870-4856-9866-88B3588F2A03Q36623655-ED18C5E0-6673-4F8C-8500-A1FAD9CD3949Q37038163-DC0C8BB5-609D-4FEA-B77C-D3E689434E10Q37134417-F2842C11-552E-431C-A203-67722DF91A79Q37196716-8D26167A-A7FF-4F1C-BB13-0167C0EB7547Q37214534-9724113E-DA69-46D1-ACCB-83D3146EDF81Q37255632-5C6C1DE8-5993-4C98-8537-B41595820B2AQ37391571-E010DF5F-26C3-402E-B409-99D32A544E5BQ37636774-33227239-2262-4E93-96F2-4B2EC4C86C7BQ37701472-51C149D6-D029-48E4-AF4A-C8025D238A09
P2860
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Alemtuzumab (Campath-1H) and C ...... prospective multicenter trial.
@en
type
label
Alemtuzumab (Campath-1H) and C ...... prospective multicenter trial.
@en
prefLabel
Alemtuzumab (Campath-1H) and C ...... prospective multicenter trial.
@en
P2093
P1433
P1476
Alemtuzumab (Campath-1H) and C ...... prospective multicenter trial
@en
P2093
Alessandra Tucci
Alessandro Levis
Andrea Gallamini
Annunziata Manna
Antonello Pinto
Atto Billio
Caterina Patti
Corrado Tarella
Emilio Iannitto
Luigi Rigacci
P304
P356
10.1182/BLOOD-2007-02-074641
P407
P577
2007-06-20T00:00:00Z